The Prioritized Drug Review and Approval Pathway pathway has been developed by the National Medical Products Administration of China.

When relevant, the agency relies on prior decisions from EU-EMA United States

The review time limit is 130 days, with 70 days applying to drugs for rare diseases with an urgent clinical need.